Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
Status:
Terminated
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This will be a non-blinded feasibility (pilot) study comparing triple therapy nebulizer vs
dry powdered inhalers (DPI) for care transitions in Chronic obstructive pulmonary disease
(COPD) exacerbation patients.
We hypothesize that patients treated in hospital and discharged on respiratory medications
administered by nebulizers will exhibit better quality of life (QoL), symptom control, and
lower COPD and all cause hospital readmission rates compared with patients treated with
respiratory medications delivered by DPI.
We aim to demonstrate that:
1. Patients treated and discharged on nebulized bronchodilators will have fewer
readmissions to hospital at 30 and 90 days compared to the group utilizing DPI
2. The nebulizer group will demonstrate a longer duration of time until hospital
readmission for COPD and all cause readmission compared to the group utilizing DPI
3. The nebulizer group will demonstrate better QoL (measured by the SGRQ - Saint George
Respiratory Questionnaire) and symptom control (as measured by the CAT & mMRC) compared
to the group utilizing DPI.
Phase:
Phase 4
Details
Lead Sponsor:
Wake Forest University Health Sciences
Treatments:
Budesonide Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Formoterol Fumarate Ipratropium Tiotropium Bromide